OptiNose presents new data on highly effective treatment for chronic rhinosinusitis

PHILADELPHIA, PA - April 17, 2009. OptiNose today announced important new results from a Phase II trial of its novel nasal drug delivery device with fluticasone for the treatment of chronic rhinosinusitis. Patients in the active treatment group experienced significant improvements in nasal symptoms, nasal discomfort and sense of smell.

Read the whole article on Science Blog

More from Science Blog